Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial

Pablo Rojo, Cinta Moraleda, Alfredo Tagarro, Sara Domínguez-Rodríguez, Lola Madrid Castillo, Luis Manuel Prieto Tato, Aranzazu Sancho López, Lilit Manukyan, Olivier Marcy, Valeriane Leroy, Alessandra Nardone, David Burger, Quique Bassat, Matthew Bates, Raoul Moh, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magallhaes, W Chris Buck, Jahit Sacarlal, Victor Musiime, Chishala Chabala, Hilda Angela Mujuru, Pablo Rojo, Cinta Moraleda, Alfredo Tagarro, Sara Domínguez-Rodríguez, Lola Madrid Castillo, Luis Manuel Prieto Tato, Aranzazu Sancho López, Lilit Manukyan, Olivier Marcy, Valeriane Leroy, Alessandra Nardone, David Burger, Quique Bassat, Matthew Bates, Raoul Moh, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magallhaes, W Chris Buck, Jahit Sacarlal, Victor Musiime, Chishala Chabala, Hilda Angela Mujuru

Abstract

Background: Pneumonia is the primary cause of death among HIV-infected children in Africa, with mortality rates as high as 35-40% in infants hospitalized with severe pneumonia. Bacterial pathogens and Pneumocystis jirovecii are well known causes of pneumonia-related death, but other important causes such as cytomegalovirus (CMV) and tuberculosis (TB) remain under-recognized and undertreated. The immune response elicited by CMV may be associated with the risk of developing TB and TB disease progression, and CMV may accelerate disease caused both by HIV and TB. Minimally invasive autopsies confirm that CMV and TB are unrecognized causes of death in children with HIV. CMV and TB may also co-infect the same child. The aim of this study is to compare the impact on 15-day and 1-year mortality of empirical treatment against TB and CMV plus standard of care (SoC) versus SoC in HIV-infected infants with severe pneumonia.

Methods: This is a Phase II-III, open-label randomized factorial (2 × 2) clinical trial, conducted in six African countries. The trial has four arms. Infants from 28 to 365 days of age HIV-infected and hospitalized with severe pneumonia will be randomized (1:1:1:1) to (i) SoC, (ii) valganciclovir, (iii) TB-T, and (iv) TB-T plus valganciclovir. The primary endpoint of the study is all-cause mortality, focusing on the short-term (up to 15 days) and long-term (up to 1 year) mortality. Secondary endpoints include repeat hospitalization, duration of oxygen therapy during initial admission, severe and notable adverse events, adverse reactions, CMV and TB prevalence at enrolment, TB incidence, CMV viral load reduction, and evaluation of diagnostic tests such as GeneXpert Ultra on fecal and nasopharyngeal aspirate samples and urine TB-LAM.

Discussion: Given the challenges in diagnosing CMV and TB in children and results from previous autopsy studies that show high rates of poly-infection in HIV-infected infants with respiratory disease, this study aims to evaluate a new approach including empirical treatment of CMV and TB for this patient population. The potential downsides of empirical treatment of these conditions include toxicity and medication interactions, which will be evaluated with pharmacokinetics sub-studies.

Trial registration: ClinicalTrials.gov , NCT03915366, Universal Trial Number U111-1231-4736, Pan African Clinical Trial Registry PACTR201994797961340.

Keywords: Child mortality; Cytomegalovirus; Empirical; Factorial; Factorial randomized clinical trial; HIV; Infants; Pneumonia; Tuberculosis; Valganciclovir.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Trial flowchart
Fig. 2
Fig. 2
Scheme for reporting adverse events

References

    1. Ateba Ndongo F, Texier G, Ida Penda C, Tejiokem MC, Tetang Ndiang S, Ndongo JA, et al. Virologic response to early antiretroviral therapy in HIV-infected infants: evaluation after 2 years of treatment in the Pediacam study, Cameroon. Pediatr Infect Dis J. 2018;37(1):78–84. 10.1097/INF.0000000000001745.
    1. Mouhari-Touré A, Mahamadou G, Kombate K, Akakpo AS, Teclessou JN, Singo A, et al. Morbidity and mortality in HIV-infected children on antiretroviral therapy in Togo. Med Sante Trop. 2018;28(1):54–60. 10.1684/mst.2018.0767.
    1. Theodoratou E, McAllister DA, Reed C, et al. Global, regional, and national estimates of pneumonia burden in HIV-infected children in 2010: a meta-analysis and modelling study. Lancet Infect Dis. 2014;14(12):1250–1258. doi: 10.1016/S1473-3099(14)70990-9.
    1. Njuguna IN, Cranmer LM, Otieno VO, Mugo C, Okinyi HM, Benki-Nugent S, et al. Urgent versus post-stabilisation antiretroviral treatment in hospitalised. Lancet HIV. 2018;5(1):e12–22. 10.1016/S2352-3018(17)30167-4.
    1. Revised WHO . Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 2014.
    1. Zampoli M, Morrow B, Hsiao N-Y, Whitelaw A, Zar HJ. Prevalence and outcome of cytomegalovirus-associated pneumonia in relation to human immunodeficiency virus infection. Pediatr Infect Dis J. 2011;30(5):413–417. doi: 10.1097/INF.0b013e3182065197.
    1. Bates M, Shibemba A, Mudenda V, Chimoga C, Tembo J, Kabwe M, et al. Burden of respiratory tract infections at post mortem in Zambian children. BMC Med. 2016;14(1):99. 10.1186/s12916-016-0645-z.
    1. Jeena PM, Govender K, Parboosing R, Adhikari M. The significance of cytomegalovirus in children with pneumonia admitted for mechanical ventilation. Int J Tuberc Lung Dis. 2017;21(12):1230–1236. doi: 10.5588/ijtld.17.0026.
    1. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109(10):783–788. doi: 10.7326/0003-4819-109-10-783.
    1. Mattioni S, Pavie J, Porcher R, Scieux C, Denis B, de Castro N, et al. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia. Int J STD AIDS. 2015;26(5):306–12. 10.1177/0956462414536146.
    1. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002;360(9338):985–90. 10.1016/S0140-6736(02)11082-8.
    1. Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulmon Med. 2013;19(3):229–237. doi: 10.1097/MCP.0b013e32835f4fe4.
    1. Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, et al. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study. Lancet HIV. 2018;5(2):e87–95. 10.1016/S2352-3018(17)30206-0. Epub 2017 Nov 23.
    1. Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, Donald P, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(3):285–95. 10.1016/S1473-3099(16)30474-1.
    1. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Geneva: World Health Organization; 2017.
    1. Oliwa JN, Karumbi JM, Marais BJ, Madhi SA, Graham SM. Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review. Lancet Respir Med. 2015;3(3):235–243. doi: 10.1016/S2213-2600(15)00028-4.
    1. Ciaranello A, Lu Z, Ayaya S, Losina E, Musick B, Vreeman R, et al. Incidence of World Health Organization Stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa Regional Analysis. Pediatr Infect Dis J. 2014;33(6):623–9. 10.1097/INF.0000000000000223.
    1. López-Varela E, Augusto OJ, Gondo K, et al. Incidence of tuberculosis among young children in rural Mozambique. Pediatr Infect Dis J. 2015;34(7):686–692. doi: 10.1097/INF.0000000000000710.
    1. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987–2002. doi: 10.1097/QAD.0000000000000802.
    1. Rennert WP, Kilner D, Hale M, Stevens G, Stevens W, Crewe-Brown H. Tuberculosis in children dying with HIV-related lung disease: clinical-pathological correlations. Int J Tuberc Lung Dis. 2002;6(9):806–813.
    1. Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016;387(10024):1198–209. 10.1016/S0140-6736(16)00546-8.
    1. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun. 2016;7:11633. 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.
    1. Fodil-Cornu N, Vidal SM. Type I Interferon Response to Cytomegalovirus Infection: The Kick-Start. Cell Host Microbe. 2008;3(2):59–61. doi: 10.1016/j.chom.2008.01.005.
    1. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The Immune Response in Tuberculosis. Ann Rev Immunol. 2013;31(1):475–527. doi: 10.1146/annurev-immunol-032712-095939.
    1. Nagu T, Aboud S, Rao M, Matee M, Axelsson R, Valentini D, et al. Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy. Int J Infect Dis. 2017;56:136–9. 10.1016/j.ijid.2017.01.022.
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2018. 2018. . Accessed 1 Sept 2021.
    1. Pocket Book of Hospital Care for Children . Guidelines for the Management of Common Childhood Illnessess. 2. Geneva: WHO Ed; 2013.
    1. World Health Organization. Integrated Management of Childhood Illness: distance learning course: World Health Organization; 2014. . Accessed 1 Sept 2021.
    1. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
    1. Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933–43. 10.1056/NEJMoa1404599. PMID: 25738669; PMCID: PMC4401811.
    1. Newberry L, O’Hare B, Kennedy N, Selman A, Omar S, Dawson P, et al. Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial. Paediatr Int Child Health. 2017;37(2):121–8. 10.1080/20469047.2016.1260891.
    1. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
    1. Sulis G, Amadasi S, Odone A, Penazzato M, Matteelli A. Antiretroviral therapy in HIV infected children with tuberculosis: a systematic review. Pediatr Infect Dis J. 2017;37(5):e117–e125. doi: 10.1097/INF.0000000000001784.
    1. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334(7585):136. 10.1136/bmj.39000.486400.55.
    1. Malhotra B, World Health Organization, Department of HIV/AIDS, Stop TB Initiative (World Health Organization) Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventative Therapy for People Living with HIV in Resource-Constrained Settings. Geneva: Department of HIV/AIDS : Stop TB Department, World Health Organization; 2011.
    1. Goussard P, Kling S, Gie RP, Nel ED, Heyns L, Rossouw GJ, et al. CMV pneumonia in HIV-infected ventilated infants. Pediatr Pulmonol. 2010;45(7):650–5. 10.1002/ppul.21228.
    1. Ruffini DD, Madhi SA. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS. 2002;16(1):105–112. doi: 10.1097/00002030-200201040-00013.
    1. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(9):851–6. . 10.1038/sj.bmt.1705341.
    1. Freeman ML, Mudd JC, Shive CL, Younes SA, Panigrahi S, Sieg SF, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection. Clin Infect Dis. 2016;62(3):392–6. 10.1093/cid/civ840.
    1. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203(10):1474–83. 10.1093/infdis/jir060.
    1. Proschan MA. Sample size re-estimation in clinical trials. Biom J. 2009;51(2):348–357. doi: 10.1002/bimj.200800266.
    1. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–523. doi: 10.1016/S1473-3099(08)70184-1.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj